Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, Michaelson JS, Rovin B, Putterman C. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006; 27:242-50.
Pitashny M, Schwartz N, Putterman C. Managing lupus: current and developing therapies. J Musculoskel Med 2006; 23:219-36.
Pitashny M, Schwartz N, Qing X, Hojaili B, Aranow C, Mackay M, Putterman C. Urinary Lipocalin-2 as a potential biomarker for human lupus nephritis. Arthritis Rheum 2007; 56:1894-903.
Wu T, Xie C, Wang HW, Zhou XJ, Schwartz N, Calixto S, Mackay M, Aranow C, Putterman C, Mohan C. Elevated urinary VCAM-1, P-selectin, soluble TNF receptor-1, and CXC chemokine ligand 16 in multiple murine lupus strains and human lupus nephritis. J Immunol 2007; 179:7166-75.
Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS, Putterman C. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007; 179:7949-58.
Schwartz N, Michaelson JS, Putterman C. Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann NY Acad Sci 2007; 1109:265-74.
Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, Hojaili B, Mackay M, Aranow C, Stohl W, Rovin BH, Michaelson JS, Putterman C. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009; 11:R143.
Rubinstein T, Pitashny M, Levine B, Schwartz N, Schwartzman J, Weinstein E, Pego-Regiosa JM, Lu TT, Isenberg D, Rahman A, Putterman C. Urinary neutrophil gelatinase associated lipocalin as a novel biomarker for disease activity in lupus nephritis. Rheumatology 2010; 49:960-71.
Schwartz N, Mitnick HJ, Nowatzky J. Headaches related to rheumatologic disease. Curr Pain Headache Rep 2013; 17:381.
Schwartz N, Putterman C, ‘Nephritogenic antibodies in systemic lupus erythematosus’, in IR Mackay, NR Rose (ed.), Encyclopedia of Medical Immunology – Autoimmune Diseases, Springer Science+Business Media, New York 2014, DOI 10.1007/978-0-387-84828-0.
Schwartz N, Goilav B, Putterman C. The pathogenesis, diagnosis and treatment of lupus nephritis. Curr Opin Rheumatol 2014; 26:502-509.
Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol 2019; 15: 137-52. DOI 10.1038/s41584-018-0156-8.
Schwartz N, Chalasani MLS, Li TM, Feng Z, Shipman WD, Lu TT. Lymphatic function in autoimmune diseases. Front Immunol 2019; 10:519. DOI: 10.3389/fimmu.2019.00519
Oláh C, Schwartz N, Denton C, Kardos Z, Putterman C, Szekanecz Z. Cognitive dysfunction in autoimmune rheumatic diseases. Arthritis Res Ther 2020; 22:78. DOI: 10.1186/s13075-020-02180-5.
Iacobas D, Wen J, Iacobas S, Schwartz N*, Putterman C* (co-senior authors). Remodeling of neurotransmission, chemokine, and PI3K-AKT signaling genomic fabrics in neuropsychiatric systemic lupus erythematosus. Genes (Basel) 2021; 12:251. doi: 10.3390/genes12020251.
Iacobas DA, Wen J, Iacobas S, Putterman C, Schwartz N. TWEAKing the hippocampus: the effects of TWEAK on the genomic fabric of the hippocampus in a neuropsychiatric lupus mouse model. Genes (Basel) 2021; 12: 1172. doi: 10.3390/genes12081172.
Kataru RP, Baik JE, Park HJ, Ly CL, Shin J, Schwartz N, Lu TT, Ortega S, Mehrara BJ. Lymphatic-specific intracellular modulation of receptor tyrosine kinase signaling improves lymphatic growth and funciton. Sci Signal 2021; 14(695):eabc0836. doi 10.1126/scisignal.abc0836.